CLEVELAND, June 25 /PRNewswire/ -- Athersys Inc., a functional genomics
and biopharmaceutical company, announced today that Dr. John Harrington,
executive vice president and chief scientific officer at Athersys is scheduled
to present at the BIO 2001 International Biotechnology Investor and Partnering
Forum.
The presentation is scheduled to take place on Wednesday, June 27, 2001 at
10:30 a.m. PT from The San Diego Convention Center in San Diego, California.
During the presentation, Dr. Harrington will provide an overview of Athersys'
business strategy, recent business development announcements, and the
Company's RAGE technology. The presentation will be broadcast live via the
Internet and can be accessed at:
http://www.informedinvestors.com/iif_forums/event.cfm?forumID=195
Following the live presentation, the Webcast will be archived for 30 days
and can be accessed at the above referenced address. More information on the
forum can be found at http://www.InformedInvestors.com or by calling
800-992-4683.
Athersys Overview
Athersys is a functional genomics and biopharmaceutical company engaged in
the study of gene function and in the development, application and
commercialization of novel research tools and therapeutic products. The
Company's RAGE (Random Activation of Gene Expression)(TM) technology platform
is a novel gene expression system that provides the unique ability to produce
protein from virtually every gene in the human genome, without requiring the
cloning of individual genes or use of cDNA libraries. RAGE greatly accelerates
the identification and validation of novel drug targets by enabling the direct
correlation of a disease process or characteristic with expression of a
specific protein. As a result, RAGE has powerful applications in functional
genomics; the generation of validated drug targets; discovery of novel
antibody drug targets; structural proteomics and rational drug design; and the
production of protein therapeutics. Athersys is developing novel therapeutic
products based on its proprietary technologies, through partnerships and
internal research and development programs. This press release and further
information on Athersys, Inc. can be found on the World Wide Web at:
http://www.athersys.com.
Statements herein that are not descriptions of historical facts are
forward-looking and subject to risk and uncertainties. Actual results could
differ materially from those currently anticipated due to a number of factors,
including risks relating to the early stage of products under development;
uncertainties related to patent protection; uncertainties relating to clinical
trials; dependence on third parties, including strategic partners,
collaborators and key personnel; and risks relating to the development and
commercialization, if any, of Athersys' proposed products (such as
effectiveness of our products, marketing, manufacturing, safety, regulatory,
patent or product liability, supply, competition and other risks).
SOURCE Athersys Inc.
 back to top
Related links:
http://www.athersys.com
http://www.InformedInvestors.com http://www.bio.org
CONTACT:
Kathryn Garvey, Director of Strategic
Planning & Investor Relations of Athersys, Inc., 216-431-9900,
ext. 223, ir@athersys.com; or Brad Miles of BMC Communications,
212-477-9007, ext. 17, for Athersys, Inc.
|
